Hydrochlorothiazide, sold under the brand name Hydrodiuril among others, is a diuretic medication used to treat hypertension and swelling due to fluid build-up. Other uses include treating diabetes insipidus and renal tubular acidosis and to decrease the risk of kidney stones in hypercalciuria. Hydrochlorothiazide is taken by mouth and may be combined with other blood pressure medications as a single pill to increase effectiveness.[3] Hydrochlorothiazide is a thiazide medication which inhibits reabsorption of sodium and chloride ions from the distal convoluted tubules of the kidneys, causing a natriuresis.[3] This initially increases urine volume and lowers blood volume. It is believed to reduce peripheral vascular resistance.[4]
Potential side effects include poor kidney function, electrolyte imbalances, including low blood potassium, and, less commonly, low blood sodium, gout, high blood sugar, and feeling lightheaded with standing.[3]
Two companies, Merck & Co. and Ciba Specialty Chemicals, state they discovered the medication which became commercially available in 1959.[5] It is on the World Health Organization's List of Essential Medicines.[6] It is available as a generic drug[3] and is relatively affordable.[7] In 2023, it was the sixteenth most commonly prescribed medication in the United States, with more than 31million prescriptions.[8][9]
Mechanism of action
Hydrochlorothiazide inhibits the sodium-chloride cotransporter in the distal convoluted tubules, which normally reabsorb 5–10% of sodium. This increases sodium delivery to the collecting ducts and reduces sodium-potassium ATPase activity, limiting sodium and water reabsorption.
The increased sodium in the tubule promotes calcium reabsorption via voltage-gated channels and the sodium-calcium exchanger, contributing to 7–10% of filtered calcium retention. Elevated sodium in the collecting ducts also triggers aldosterone-mediated reabsorption of sodium and excretion of potassium, producing diuretic effects.[10][11]
In adults, hydrochlorothiazide acts within 2 hours, peaks at 4 hours, and lasts 6–12 hours. It is excreted primarily by the kidneys, so severe renal impairment (creatinine clearance <10) reduces effectiveness. Initial blood pressure reduction occurs through volume loss, while long-term effects involve vasodilation and decreased peripheral resistance, though the exact mechanism is unclear.[12]
Medical uses
Hydrochlorothiazide is used for the treatment of hypertension, congestive heart failure, symptomatic edema, diabetes insipidus, renal tubular acidosis.[3] It is also used for the prevention of kidney stones in those who have high levels of calcium in their urine.[3]
Multiple studies suggest hydrochlorothiazide could be used as initial monotherapy in people with primary hypertension; however, the decision should be weighed against the consequence of long-term adverse metabolic abnormalities.[13][14] Doses of hydrochlorothiazide of 50 mg or less over four years reduced mortality and development of cardiovascular diseases better than high-dose hydrochlorothiazide (50 mg or more) and beta-blockers. A 2019 review supported equivalence between drug classes for initiating monotherapy in hypertension, although thiazide or thiazide-like diuretics showed better primary effectiveness and safety profiles than angiotensin-converting enzyme inhibitors and non-dihydropyridine calcium channel blockers.[13]
Low doses (50 mg or less) of hydrochlorothiazide as first‐line therapy for hypertension were found to reduce total mortality and cardiovascular disease events over a four-year study.[15] Hydrochlorothiazide appears be more effective than chlorthalidone in preventing heart attacks and strokes.[16] Hydrochlorothiazide is less potent but may be more effective than chlorthalidone in reducing blood pressure.[16][17] More robust studies are required to confirm which drug is superior in reducing cardiovascular events.[18] Side effect profile for both drugs appear similar and are dose dependent.[16]
Hydrochlorothiazide is also sometimes used to prevent osteopenia and treat hypoparathyroidism,[19] hypercalciuria, Dent's disease, and Ménière's disease.
A low level of evidence, predominantly from observational studies, suggests that thiazide diuretics have a modest beneficial effect on bone mineral density and are associated with a decreased fracture risk when compared with people not taking thiazides.[20][21][22] Thiazides decrease mineral bone loss by promoting calcium retention in the kidney, and by directly stimulating osteoblast differentiation and bone mineral formation.[23]
The combination of fixed-dose preparation such as losartan/hydrochlorothiazide has added advantages of a more potent antihypertensive effect with additional antihypertensive efficacy at the dose of 100 mg/25 mg when compared to monotherapy.[24][25]
Adverse effects
Package inserts contain vague and inconsistent data surrounding the use of thiazide diuretics in patients with allergies to sulfa drugs, with little evidence to support these statements.[28] A retrospective cohort study conducted by Strom et al. concluded that there is an increased risk of an allergic reaction occurring in patients with a predisposition to allergic reactions in general rather than cross reactivity from structural components of the sulfonamide-based drug.[29] Prescribers should examine the evidence carefully and assess each patient individually, paying particular attention to their prior history of sulfonamide hypersensitivity rather than relying on drug monograph information.[30]
There is an increased risk of non-melanoma skin cancer.[31] In August 2020, the Australian Therapeutic Goods Administration required the Product Information (PI) and Consumer Medicine Information (CMI) for medicines containing hydrochlorothiazide to be updated to include details about an increased risk of non-melanoma skin cancer.[32] In August 2020, the U.S. Food and Drug Administration (FDA) updated the drug label about an increased risk of non-melanoma skin cancer (basal cell skin cancer or squamous cell skin cancer).[33]
In November 2024, International Agency for Research on Cancer (IARC) classified hydrochlorothiazide, voriconazole and tacrolimus as group 1 carcinogens.[34][35]
- Hypokalemia, or low blood levels of potassium are an occasional side effect. It can be usually prevented by potassium supplements or by combining hydrochlorothiazide with a potassium-sparing diuretic
- Other disturbances in the levels of serum electrolytes, including hypomagnesemia (low magnesium), hyponatremia (low sodium), and hypercalcemia (high calcium)
- Hyperuricemia (high levels of uric acid in the blood). All thiazide diuretics including hydrochlorothiazide can inhibit excretion of uric acid by the kidneys, thereby increasing serum concentrations of uric acid. This may increase the incidence of gout in doses of ≥ 25 mg per day and in more susceptible patients such as male gender of <60 years old.[25][26][27]
- Hyperglycemia, high blood sugar
- Hyperlipidemia, high cholesterol and triglycerides
- Headache
- Nausea/vomiting
- Photosensitivity
- Weight gain
- Pancreatitis
Society and culture
Brand names
Hydrochlorothiazide is available as a generic drug under a large number of brand names, including Apo-Hydro, Aquazide, BPZide, Dichlotride, Esidrex, Hydrochlorot, Hydrodiuril, HydroSaluric, Hypothiazid, Microzide, Oretic and many others.
To reduce pill burden and in order to reduce side effects, hydrochlorothiazide is often used in fixed-dose combinations with many other classes of antihypertensive drugs such as:
- ACE inhibitors – e.g. Prinzide or Zestoretic (with lisinopril), Co-Renitec (with enalapril), Capozide (with captopril), Accuretic (with quinapril), Monopril HCT (with fosinopril), Lotensin HCT (with benazepril), etc.
- Angiotensin receptor blockers – e.g. Hyzaar (with losartan), Co-Diovan or Diovan HCT (with valsartan), Teveten Plus (with eprosartan), Avalide or CoAprovel (with irbesartan), Atacand HCT or Atacand Plus (with candesartan), etc.
- Beta blockers – e.g. Ziac or Lodoz (with bisoprolol),[36] Nebilet Plus or Nebilet HCT (with nebivolol), Dutoprol or Lopressor HCT (with metoprolol), etc.
- Direct renin inhibitors – e.g. Co-Rasilez or Tekturna HCT (with aliskiren)
- Potassium sparing diuretics – Dyazide and Maxzide triamterene[37]
Sport
Use of hydrochlorothiazide is prohibited by the World Anti-Doping Agency for its ability to mask the use of performance-enhancing drugs.[38] In July 2025, women's marathon world record holder Ruth Chepng'etich was provisionally suspended by the Athletics Integrity Unit after testing positive for hydrochlorothiazide.[39]
References
- Hydrochlorothiazide Use During Pregnancy Drugs.com, 30 July 2019, retrieved 19 January 2020^
- Absorption, metabolism, and excretion of hydrochlorothiazide Clinical Pharmacology and Therapeutics, May 1976^
- Hydrochlorothiazide Drugs.com, 15 November 2022, retrieved 31 May 2023^
- Mechanisms for blood pressure lowering and metabolic effects of thiazide and thiazide-like diuretics Expert Review of Cardiovascular Therapy, June 2010^
- The evolution of drug discovery: from traditional medicines to modern drugs Wiley-VCH, 2011^
- The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) World Health Organization, 2023^
- Best drugs to treat high blood pressure The least expensive medications may be the best for many people November 2014, retrieved 10 January 2015^
- Top 300 of 2023 ClinCalc, retrieved 12 August 2025^
- Hydrochlorothiazide Drug Usage Statistics, United States, 2014 - 2023 ClinCalc, retrieved 12 August 2025^
- Distal convoluted tubule Clinical Journal of the American Society of Nephrology, December 2014^
- Renal secretion of hydrochlorothiazide involves organic anion transporter 1/3, organic cation transporter 2, and multidrug and toxin extrusion protein 2-K American Journal of Physiology. Renal Physiology, October 2019^
- StatPearls StatPearls Publishing, 2025, retrieved 2025-11-23^
- Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis Lancet, November 2019^
- Pharmacotherapy for hypertension in adults aged 18 to 59 years The Cochrane Database of Systematic Reviews, August 2017^
- First-line drugs for hypertension The Cochrane Database of Systematic Reviews, April 2018^
- Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension JAMA Internal Medicine, April 2020^
- Meta-analysis of dose-response relationships for hydrochlorothiazide, chlorthalidone, and bendroflumethiazide on blood pressure, serum potassium, and urate Hypertension, June 2012^
- Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis Hypertension, April 2011^
- Long-term follow-up of patients with hypoparathyroidism The Journal of Clinical Endocrinology and Metabolism, December 2012^
- Thiazide diuretics and the risk of hip fracture The Cochrane Database of Systematic Reviews, October 2011^
- Thiazide diuretic usage and risk of fracture: a meta-analysis of cohort studies Osteoporosis International, July 2018^
- Bone mineral density changes among women initiating blood pressure lowering drugs: a SWAN cohort study Osteoporosis International, March 2016^
- Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone Journal of the American Society of Nephrology, September 2007^
- Antihypertensive effects of two fixed-dose combinations of losartan and hydrochlorothiazide versus hydrochlorothiazide monotherapy in subjects with ambulatory systolic hypertension American Journal of Hypertension, December 2003^
- Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension The Cochrane Database of Systematic Reviews, May 2014^
- Use of diuretics and the risk of gouty arthritis: a systematic review Seminars in Arthritis and Rheumatism, June 2012^
- Comparison of new-onset gout in adults prescribed chlorthalidone vs. hydrochlorothiazide for hypertension Journal of Clinical Hypertension, December 2014^
- Sulfonamide cross-reactivity: fact or fiction? The Annals of Pharmacotherapy, February 2005^
- Absence of cross-reactivity between sulfonamide antibiotics and sulfonamide nonantibiotics The New England Journal of Medicine, October 2003^
- An evidence-based approach for providing cautionary recommendations to sulfonamide-allergic patients and determining cross-reactivity among sulfonamide-containing medications Journal of Clinical Pharmacy and Therapeutics, June 2013^
- Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark Journal of the American Academy of Dermatology, April 2018^
- Hydrochlorothiazide Therapeutic Goods Administration (TGA), 24 August 2020, retrieved 22 September 2020^
- FDA approves label changes to hydrochlorothiazide U.S. Food and Drug Administration (FDA), 20 August 2020, retrieved 28 August 2020^
- Carcinogenicity of hydrochlorothiazide, voriconazole, and tacrolimus The Lancet. Oncology, January 2025^
- List of Classifications IARC, retrieved 12 April 2025^
- List of nationally authorised medicinal products: Active substance: bisoprolol / hydrochlorothiazide Procedure no.: PSUSA/00000420/202111 Ema.europa.eu, retrieved 16 July 2022^
- Triamterene and Hydrochlorothiazide MedlinePlus, 1 January 2020, retrieved 1 January 2020^
- Prohibited List World Anti-Doping Agency, January 2018^
- Ruth Chepngetich: Women's marathon world record holder suspended for doping BBC Sport, 17 July 2025, retrieved 18 July 2025^